JCR Pharmaceuticals Co., Ltd. announced that its Board of Directors resolved at a meeting held on April 25, 2024 change personnel change as follows: Change of Corporate Officer (As of June 26, 2024). The new title of Anne Bechet is Senior Corporate Officer, Executive Director, Clinical Development, General Manager, JCR Europe B.V., Director, JCR Luxemburg S. A and CEO, JCR USA Inc. Current Title is Clinical Development (Acting Officer), General Manager, JCR Europe B.V. and Director, JCR Luxemburg S.A.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
595 JPY | -1.82% |
|
+2.06% | -49.23% |
06-24 | JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from S&P Japan 500 | CI |
05-31 | JCR Pharmaceuticals' Full-Year Profit Up 46% | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.23% | 461M | |
+55.19% | 801B | |
+47.26% | 631B | |
-6.09% | 359B | |
+21.92% | 337B | |
+18.40% | 245B | |
+3.64% | 231B | |
+12.98% | 219B | |
+10.86% | 171B | |
-2.78% | 161B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024